Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Unknown 2Withdrawn 1Completed 1

Sponsor Class

OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Breast 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3Ovarian Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hydralazine × Gynecologic × Clear all
NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

National Institute of Cancerología

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00532818 2009-03-30

Hydralazine Valproate for Cervical Cancer

National Institute of Cancerología

Phase 3 Unknown
143 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00533299 2007-09-21

Hydralazine Valproate for Ovarian Cancer

National Institute of Cancerología

Phase 3 Unknown
211 enrolled
Gynecologic

Ovarian Neoplasms

NCT00404326 2006-11-28

Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer

National Institute of Cancerología

Phase 2 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡